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Abstract Oxaliplatin 100 mg/m2 iv on day 1, and cape-
citabine 1,000 mg/m2 orally bid from day 1 (evening) to
day 11 (morning) were administered every 2 weeks
(OXXEL regimen) to 38 patients as ﬁrst-line treatment
for metastatic colorectal carcinoma. A total of 318 cycles
were administered, with a median of 8 (range, 4–12) cy-
cles per patient. Response rate (RR) was 45% (95%
conﬁdence interval (CI), 29%–62%), with 7 complete
responses and 10 partial responses; furthermore, 12 pa-
tients showed a stable disease, so that a disease control
was achieved in 29 (76%) patients. RR was greater
among patients with performance status 0 (52%), with-
out weight loss (52%), younger than 65 years (50%), and
previously unexposed to adjuvant chemotherapy (48%),
while no correlation was found with the actually deliv-
ered oxaliplatin dose intensity. Overall, haematological
side eﬀects were negligible, with no case of grade 4 tox-
icity, and only one patient suﬀering from an episode of
grade 3 neutropenic fever. Severe anaemia occurred in 4
(11%) patients, and grade 3 neuropathy aﬀected 9 (24%)
patients. Median progression-free survival was 7.9 (95%
CI, 6.2–9.6) months, and median overall survival has not
been reached yet. In conclusion, the OXXEL regimen
resulted safe and active, and it deserves further evalua-
tion in metastatic colorectal cancer patients.
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Introduction
The combination of oxaliplatin (OXA) with infusional
5-ﬂuorouracil and leucovorin (FU/LV) (FOLFOX4
regimen) represents a new golden standard both in the
adjuvant and in the palliative treatment of colon cancer.
For patients with metastatic spread, FOLFOX4 was
superior to IFL (irinotecan plus bolus FU/LV) in terms
of response rate (RR), progression-free (PFS) and
overall survival (OS), showing also a better toxicity
proﬁle [7].
French investigators have previously observed that
activity of FOLFOX was related with OXA dosage and
dose intensity (DI). Indeed, they reported a greater RR
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among patients treated with an OXA dosage ‡ 85 mg/m2
every 2 weeks than for those receiving a lower DI (39%
vs. 19%) [11]. Increasing the OXA dosage to 130 mg/m2
in the FOLFOX7 biweekly regimen, a RR in 42% of
patients treated in second line has been reported, asso-
ciated with a median survival of 16.1 months, at a price
of an acceptable toxicity [12]. However, delivery of
FOLFOX regimen requires an indwelling or totally im-
planted central venous catheter and disposable infusional
devices and/or pumps, which increase the treatment cost,
may be associated with vascular complications, and
cause some discomfort for the outpatient management.
Capecitabine is a parent compound of FU, which can
be administered orally at a recommended dose of
1,250 mg/m2 bid, 12-h apart, for two consecutive weeks,
and 1 week of rest. This drug has been randomly com-
pared with standard FU/LV given i.v. monthly (Mayo
Clinic regimen) either as adjuvant treatment to radical
surgery and as palliative therapy. In two trials carried
out in metastatic patients [9, 18], capecitabine obtained a
higher RR (23% vs. 15%, and 27% vs. 18%, respec-
tively) with an acceptable toxicity proﬁle: hand-foot
syndrome aﬀected on the whole 16% of patients, while
severe diarrhoea occurred in 13% of them, a proportion
signiﬁcantly lower than that of the control arm [17].
Based on these observations, capecitabine has been
tested in several phase II trials in combination with
OXA (XELOX regimen) in the ﬁrst and second-line
treatment of metastatic patients. In the largest of these
studies, 97 patients were treated in ﬁrst line with OXA
130 mg/m2 on day 1, and capecitabine 2,000 mg/m2
orally from day 1 to day 14, recycling every 3 weeks
[2]. These investigators reported a 55% RR, and a
19.5-month median OS, with a negligible occurrence of
grade ‡3 haematological and non-haematological side
eﬀects. A grade 3 neuropathy was reported in 16% of
patients, while the typical hand-foot syndrome was
observed in only 2% of them. In a Swiss phase II
study, 26 pretreated and 43 chemonaive patients re-
ceived OXA 130 mg/m2 on day 1, and capecitabine
2,500 mg/m2 on day 1 to 14 every 3 weeks. A 49%
RR, and a median OS of 17.1 months, were reported
among unpretreated patients. However, 35% of
chemonaive patients, and 50% of pretreated patients,
suﬀered from grade ‡3 diarrhoea [1]. Slightly lower
dosages (OXA 120 mg/m2 plus capecitabine 2,400 mg/
m2 for 14 days every 3 weeks) were explored in an
other phase II study in ﬁrst line. This combination
yielded a 44% RR, and a median OS of 20 months,
but severe diarrhoea aﬀected 28% of patients, sug-
gesting a further reduction of capecitabine dosage [19].
Recently, also a diﬀerent schedule of OXA (70 mg/m2
given on days 1 and 8) has been explored in combi-
nation with capecitabine 2,000 mg/m2 daily for 2 of
3 weeks in a phase II randomized trial. This regimen
was reported to obtain a 50.7% RR among 75 un-
pretreated patients [8].
With these premises in mind, we decided to assess the
activity and tolerability of a combination of OXA and
capecitabine given in a biweekly schedule (OXXEL
regimen), trying to increase OXA DI while keeping un-
changed capecitabine DI. The biweekly schedule should
also allow for a more dose-dense treatment in compar-
ison with the 3-weekly regimen.
Patients and methods
Patients
Patients were eligible for this study if they met the
following inclusion criteria: histologically proven
diagnosis of colorectal carcinoma; age ‡ 18 years;
Eastern Cooperative Oncology Group performance
status (PS) £ 2; life expectancy ‡ 3 months; at least
one bidimensionally measurable metastatic lesion;
adequate bone marrow reserve (neutrophils ‡ 2.0·109/
L, platelets ‡ 100·109/L, and haemoglobin serum
concentration ‡10 g/dL); normal liver function (bili-
rubin < 1.25·upper normal limit [UNL], ALT and
AST < 2.5·UNL in the absence of liver metastasis, or
bilirubin < 1.25, ALT and AST < 5·UNL in the case
of liver metastasis); normal renal function (serum
creatinine < 1.5·UNL). Exclusion criteria were: pre-
vious chemotherapy for the metastatic disease (ad-
juvant treatment was permitted, provided that at least
6 months had elapsed from its discontinuation);
uncontrolled metabolic disorders or active infections;
inability to swallow oral medications; inﬂammatory
bowel diseases, signiﬁcant diarrhoea during the last
week or bowel obstruction; previous total colectomy or
ileostomy; severe cardiac arrhythmia, uncontrolled
congestive cardiac failure, severe ischaemic heart dis-
ease, or acute myocardial infarction in the last
6 months; symptomatic cerebral metastasis. All pa-
tients gave an informed consent to participate in this
trial, which was approved by the Independent Ethical
Committee of the National Tumour Institute of Na-
ples.
Initial assessment
Medical history, physical examination, performance
status, and symptoms of disease were registered at pa-
tient’s entry. Blood cell count (BCC), white cell diﬀer-
ential, biochemistry, urinalysis, and serum CEA basal
value were assessed within one week from initial ther-
apy. Chest X-ray and ECG were routinely performed.
Target lesions were measured with computed tomogra-
phy (CT) or magnetic resonance imaging (MRI) scans
carried-out within 1 month before study entry.
Assessment of toxicity and activity
BCC was performed weekly, while biochemistry was
repeated at the beginning of each cycle. Physical status
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and assessment of toxicity of previous cycle were
checked before the start of the next cycle. Toxicity was
scored according to WHO criteria [13], but a speciﬁc
scale was used for OXA neurotoxicity: grade 1 was the
occurrence of paraesthesia and/or dysaestesia lasting less
than 1 week; grade 2 was the occurrence of paraesthesia
and/or dysaestesia lasting more than 1 week; grade 3
was the occurrence of paraesthesia and/or dysaestesia
persisting for more than 2 weeks; and grade 4 was
neurotoxicity with pain and/or functional impairment.
The worst toxicity suﬀered by each patient during the
whole treatment was recorded.
Evaluation of activity on target lesions with CT or
MRI scan was done after every four cycles. Responses
were classiﬁed according to WHO criteria [13]. PFS was
the time elapsed from the date of initial therapy to the
date of tumour progression or death. Patients who dis-
continued study medication for reasons diﬀerent from
progression were censored for PFS analysis. OS was the
time elapsed from the date of enrolment into the study
to the date of death, or last follow-up.
Treatment
OXA 100 mg/m2 was administered diluted in 500 mL
of 5% DW solution over 2 h on day 1; capecitabine
1,000 mg/m2 was assumed orally bid, 12 h apart, within
30 min after the end of the breakfast and evening meal,
from day 1 (evening) to day 11 (morning). The total
daily dose was rounded for a combination of 500 and
150 mg tablets. Cycles were repeated every 2 weeks.
Doses were unchanged throughout the whole treat-
ment, unless a grade 3 non-haematological toxicity
occurred. In this case, treatment was discontinued, and
than resumed only after a complete recovery, with a
20% OXA dose reduction and a 25% capecitabine dose
reduction. In the case of grade 4 non-haematological
toxicity (except for alopecia), grade 4 neutropenia or
thrombocytopenia lasting more than one week, or
febrile neutropenia, treatment was deﬁnitely inter-
rupted. The experimental treatment was planned for a
maximum of 12 cycles. In the case of progression,
second line treatment was left at the discretion of the
attending physician.
Statistical considerations and sample size
RR was the main end-point of this phase II trial. We
adopted a two-stage mini-max design [15]: deﬁning as
30% the minimum RR expected for the experimental
treatment, and as alternative of clinical interest a 50%
RR, at least 17 responses among a total of 39 patients
were needed for accepting this hypothesis, with an alpha
error < 0.05 and an 80% power (1-beta). RR (with 95%
CI) [4] was calculated on all eligible patients according
to intention-to-treat analysis. Actuarial PFS and OS
times were estimated using actuarial method [10].
Results
Patients
From September 6, 2003, to April, 24, 2004, 39 patients
were accrued into this trial by nine centres. After regis-
tration, one patient was found to be ineligible, because
of previous exposure to chemotherapy for the metastatic
disease, leaving 38 patients assessable for activity and
toxicity. Main characteristics of these patients are re-
ported in Table 1. Most patients (71%) were males, their
median age was 62 (range, 35–80) years. All patients had
a fairly good PS (0 in 29 patients, 1 in 9 patients). Eleven
patients had previously received adjuvant chemotherapy
(FU/LV, 10 cases; FOLFIRI, 1 case). Twenty-two
(55%) patients had only one site of disease, and liver was
involved in 25 (66%) patients.
Extent of treatment exposure
A total of 318 cycles were administered, with a median
of 8 (range, 4–12) cycles/patient. All patients received at
least 4 cycles of treatment, 26 (68%) patients were
treated up to 8 cycles, and 8 (21%) patients received a
maximum of 12 cycles.
Treatment discontinuation occurred according to
protocol’s rules in 31 patients. Three patients refused
further treatment after 7 (2 cases) and 8 (1 case) cycles,
respectively, while three patients went oﬀ treatment for
toxicity: one patient suﬀered from severe diarrhoea
Table 1 Characteristics of patients
Characteristics No. Percentage
Eligible patients 38 100
Males 27 71
Females 11 29
Median age (range) in years, 62 (35 – 80)
Performance status (ECOG)
0 29 76
1 9 24
Primary site
Colon 26 68
Rectum 12 32
Previous surgery 27 71
Previous adjuvant treatment
FAFU 10 26
FOLFIRI 1 2
Previous weight loss > 5% 7 18
Presence of symptoms 10 26
Number of disease sites
1 21 55
2 9 24
3+ 8 21
Liver 25 66
Lung 9 23
Lymph nodes 9 23
Peritoneal 4 10
CEA > 5 ng/mL 29 76
CEA > 100 ng/mL 12 31
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requiring hospitalization and forced rehydration, but he
eventually recovered from this toxicity; another patient
discontinued her treatment after four cycles for a per-
sistent grade 3 liver toxicity (increase of serum ASAT
and ALAT); and a third patient was withdrawn for
persistent neurosensory toxicity after 10 cycles (OXA
cumulative dose, 949 mg/m2). A last patient, after
achieving a substantial shrinkage of hepatic deposits
after 8 cycles, underwent radical liver surgery.
Median dose intensity (DI) over the ﬁrst 4 cycles was
46 (range, 31–56) mg/m2/week for OXA, and 9.2 (range,
1.0–10.8) g/m2/week for capecitabine. Corresponding DI
over 8 cycles were 42 mg/m2/week (range, 29–50) and
8.9 (range, 3.5–10.7) respectively. Mean cumulative
dosage of OXA was 832 (range, 383–1,200) mg/m2,
while mean cumulative dosage of capecitabine was 162
(range, 8.0–250) g/m2.
Activity
A complete response (CR) was achieved in 7 patients,
and a partial response (PR) in 10 patients, giving an
RR of 45% (95% CI, 29%–62%) Responses were ob-
served after a median of 2.3 (range, 1.8–7.2) months,
and 11 of 17 (69%) patients achieved such result within
4 months from initial therapy. In all but one patient,
who underwent surgical liver resection earlier, re-
sponses were conﬁrmed 2 months after their ﬁrst
assessment. Median duration of responses was
5.5 months. Furthermore, 12 patients were classiﬁed in
stable disease. On the whole, 29 (76%) patients
achieved at least a control of tumour growth (response
or stabilization) with the treatment on study. More-
over, we would report that 8 of 12 (66%) patients with
a basal CEA value ‡ 100 ng/mL showed a > 50% drop
of this value during treatment.
Analysis of treatment eﬀect showed that RR was
higher in patients with PS 0 as opposed to PS 1 (52%
vs. 22%), for patients without previous weight loss
(52% vs. 14%), for patients younger than 65 years
(50% vs. 33%), and for those unexposed to adjuvant
chemotherapy (48% vs. 36%). On the contrary,
activity was not substantial diﬀerent among patients
with only one disease site (48%) and those with two or
more sites (41%). Noteworthy, lung metastases also
showed a high response rate with this treatment
(44%).
Despite the fact that the regimen was intended as a
more dose-dense treatment, and it was devised with the
aim of intensifying the OXA delivery, no apparent cor-
relation between RR and OXA DI was seen. Indeed, RR
was 40% among patients receiving an OXA DI4 of at
least 46 mg/m2/week (which was the median actually
delivered DI over the ﬁrst 4 cycles) in comparison with
44% among those receiving a lower DI4.
Toxicity
Worst acute toxicity registered for each patient is re-
ported in Table 3. Overall, haematological side eﬀects
were negligible, with no case of grade 4 toxicity, and
only a patient suﬀering from an episode of grade 3
neutropenic fever. Some decrease in haemoglobin serum
level occurred during treatment in 15 (39%) patients,
but it was of grade 3 in only 4 of them (11%). As for
non-haematological side eﬀects, gastrointestinal toxicity
was quite mild: only 5 (13%) patients suﬀered from se-
vere diarrhoea, which required hospitalisation in one
case. Moreover, we would underline that the typical
hand-foot syndrome caused by capecitabine was very
rare and mild. This ﬁnding might be explained by the
shorter exposure to capecitabine with our regimen in
comparison with the 2-week-on and 1-week-oﬀ schedule.
Thirty (79%) patients complained of some neurotoxic-
ity, which was of grade ‡ 3 in 9 (24%) of them. As
mentioned, this toxicity forced OXA discontinuation in
one case. Severe peripheral neuropathy was clearly dose-
dependent, because it occurred in 7 of 23 (30%) patients
treated with an OXA cumulative dosage ‡ 800 mg/m2,
as opposed to only 2 of 15 (13%) patients receiving a
lower cumulative dosage.
Follow-up
As of October 30, 2004, with a median follow-up of 10
(range, 6–13) months, 19 (50%) patients have shown
Table 2 Activity reported among 38 patients (intent-to-treat
analysis)
Response No. Percentage
Complete response 7 18
Partial response 10 26
No change 12 32
Progressive disease 8 21
Not assessed 1 3
Total patients 38 100
Overall response rate (95% CI) 45%
(29–62%)
Table 3 Acute toxicity by patients (n=38)
Toxicity WHO grade (number
of patients)
3+4 (%)
1 2 3 4
Neutropenia 9 3 1 0 3
Febrile neutropenia – – 1 0 3
Thrombocytopenia 6 4 3 0 8
Anaemia 6 5 4 0 11
Vomiting 13 8 0 0 0
Diarrhoea 9 5 4 1 13
Stomatitis 4 1 0 0 0
Hair loss 1 5 0 0 0
Skin 3 2 0 0 0
Liver 8 3 1 0 3
Neuropathy (Le´vi scale) 12 9 8 1 24
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tumour progression; therefore, the estimated median
PFS time was 7.9 (95% CI, 6.2–9.6) months. As salvage
treatment, nine patients received irinotecan-based che-
motherapy, and one patient underwent a local radio-
therapy. At the time of this analysis, only two patients
had died because of their cancer; therefore, the median
OS has not been reached yet.
Discussion
This study aimed at assessing the tolerability and
activity of a combination of OXA and capecitabine
recycled every 2 weeks in patients with metastatic colo-
rectal carcinoma. Results of this trial demonstrated the
eﬃcacy of this treatment, which yielded a major re-
sponse in 45% of patients. We recognize that most of
our patients showed favourable baseline characteristics,
which were associated with a higher RR. However, we
would underline the activity reported by this treatment
also in patients with more than one site of disease (41%).
Moreover, we believe it is worth noting the activity we
have seen in lung metastases (44%), which are usually
less sensitive to cytotoxic treatment.
This activity was obtained with acceptable occurrence
of side eﬀects: haematological toxicity was negligible,
and diarrhoea and hand-foot syndrome were usually
mild. These results might be explained by the shorter
exposure to capecitabine in our biweekly regimen
(10 days) as compared with the 3-weekly schedule
(14 days). Indeed, a strategy of increasing the dose
intensity of capecitabine has been pursued in a previous
phase II randomized trial: OXA 85 mg/m2 was given on
day 1, while capecitabine 3,500 mg/m2 was administered
daily for 7 days, recycling every 2 weeks. This biweekly
regimen was able to deliver a 34% higher dose intensity
of capecitabine in comparison with the 3-weekly
administration of OXA 130 mg/m2 on day 1, and
capecitabine 2,000 mg/m2 daily for 14 days. Interest-
ingly, occurrence and severity of toxicity were similar
with the two regimens. This good tolerability has been
explained by the longer overall ‘‘drug holidays’’ with the
biweekly dose-intense capecitabine regimen as opposed
to the 3-weekly regimen. Moreover, a greater activity
(higher RR, longer PFS) was reported with the biweekly
regimen [14].
In our trial, we have noted that peripheral neurop-
athy aﬀected most of our patients, and grade ‡ 3 oc-
curred in 24% of them. Also in our experience,
neurotoxicity was related with the cumulative dosage of
OXA. Since only responder patients received the study
medication for as long as for 12 cycles, we may infer
that peripheral neuropathy could be considered as the
price to be paid for obtaining a clinical beneﬁt from
this treatment. On the other hand, most responses were
seen in our series within 4 months of treatment;
therefore, a possible way to circumvent the occurrence
of this side eﬀect could be planning a dose reduction
(or even discontinuation) of OXA after an intensive
administration over 6–8 cycles, and its eventual rein-
troduction thereafter. Such a policy of OXA stop and
go has been assessed in a randomized study (OPTI-
MOX trial) comparing the FOLFOX7 regimen (which
include OXA 130 mg/m2 in each cycle) with the stan-
dard FOLFOX4 regimen: in this trial, severe neuro-
toxicity occurred in 13% of patients in the experimental
arm as opposed to 19% of the control arm [5].
However, putting our results in the context of other
experiences with this combination, it could be argued
that the OXXEL regimen yielded a RR and a PFS
similar to those obtained with the 3-weekly schedule.
Indeed, RRs ranging from 44% to 55%, and median
PFS times included between 5.9 months and
8.2 months, have been reported with the XELOX regi-
men [1, 2, 19]. Moreover, we have not seen in our trial a
correlation between activity and OXA DI that could
justify the biweekly recycling. However, the number of
patients was small, and a dose-eﬀect relationship cannot
be ruled out by our ﬁndings.
On the other hand, we would underline that severe
diarrhoea and skin toxicity were quite uncommon with
the OXXEL as compared with their reported frequencies
with the XELOX regimen. Of course, a positive impact
on patient’s quality of life could support our choice. The
present pilot trial was not designed to give an answer to
this hypothesis; therefore, we have set up the SICOG
0401 randomized trial, which is currently comparing in
terms of eﬃcacy, toxicity and quality of life the OXXEL
regimen with our OXAFAFU reference treatment [3].
Other ongoing phase III trials are also comparing the
XELOX and FOLFOX4 regimens, with or without the
addition of bevacizumab, either in the adjuvant and in the
palliative setting. Results of these studies will elucidate
whether capecitabine could deﬁnitely replace FU/LV in
combination with OXA. Moreover, exciting results have
recently been reported combining inhibitors of the epi-
dermal growth factor receptor (EGFR) pathway with the
FOLFOX4 regimen in metastatic patients. Indeed, the
addition of weekly cetuximab to the FOLFOX4 has been
reported to obtain an objective response in 70% of pa-
tients selected on the basis of the positive EGFR expres-
sion on tumour [16]. Moreover, the FOLFOX4 regimen
combined with oral geﬁtinib showed activity in 78% of
patients previously unexposed to chemotherapy for their
metastatic disease, and in 36% of previously treated pa-
tients [6]. On the basis of our preliminary safety and
activity data, we believe that also the OXXEL regimen
could serve as a backbone for assessing the combination
of cytotoxic and targeted biologic treatments in meta-
static colorectal cancer patients.
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